Pharmaceuticals

Factor XII Inhibitors Market Analysis With Focus On Growth Potential And Future Outlook

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Factor XII Inhibitors Market From 2026 To 2030?

The factor xii inhibitors market size has undergone rapid expansion in recent years. It is anticipated to grow from $1.4 billion in 2025 to $1.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. The growth observed in the historic period is attributable to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the inherent limitations of traditional anticoagulants, early-stage clinical success achieved with fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $2.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is attributable to the expansion of late-stage clinical trials, a rising demand for safer antithrombotic therapies, increased adoption of precision medicine, growing regulatory support for novel anticoagulants, and the extension of FXII inhibitors into inflammatory indications. Major trends identified for this period include the increasing development of non-bleeding anticoagulant therapies, a heightened focus on targeted coagulation pathway modulation, growing clinical evaluation of FXII selective inhibitors, the expansion of RNA-based and peptide therapeutics, and enhanced utilization of precision drug design.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Key Factors Are Driving The Factor XII Inhibitors Market Growth?

The increasing occurrence of thrombotic disorders is anticipated to fuel the expansion of the factor XII inhibitors market in the coming years. Thromboembolic disorders are conditions characterized by the formation of blood clots in veins or arteries, which can obstruct blood flow and lead to serious health issues. The prevalence of these disorders is growing due to an increase in sedentary lifestyles, contributing to poor blood circulation and a heightened risk of clot formation. Factor XII inhibitors aid in preventing atypical clot development in thrombotic disorders by obstructing the contact activation pathway without interfering with normal hemostasis. This approach enables effective control of thrombosis with a reduced risk of bleeding. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that approximately 900,000 individuals in the United States are impacted by venous thromboembolism, with an estimated 60,000-100,000 Americans dying annually, and many others suffering from long-term complications. Consequently, the rising incidence of thrombotic disorders is propelling the growth of the Factor XII inhibitors market.

How Is The Factor XII Inhibitors Market Segmented Across Different Segment Categories?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Which Trends Are Guiding The Direction Of The Factor XII Inhibitors Market?

Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the goal of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics that function by inhibiting activated factor XII, thereby preventing abnormal clot formation while simultaneously preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a biopharmaceutical company based in Germany, obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks associated with hereditary angioedema (HAE). It operates by targeting activated factor XIIa, which is a key contributor to the initiation of HAE attacks, and is administered conveniently via a subcutaneous injection pen.

Which Organizations Play A Role In The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Get The Full Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Geographic Region Dominates The Factor XII Inhibitors Market?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Factor XII Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795